A Randomized, Double-Blind, Placebo-Controlled, Multiple-dose Escalation Phase I Study of Genakumab for Injection in Chinese Healthy Adults
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Firsekibart (Primary)
- Indications Interstitial lung diseases
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 01 Apr 2025 Status changed from recruiting to completed.
- 13 Jun 2023 New trial record